Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies

Abstract Background Mouse double minute‐2 homolog (MDM2) plays a key role in downregulating p53 activity in hematologic malignancies, and its overexpression is associated with poor outcomes. Methods This phase 1 study assessed the safety and efficacy of different dosing regimens of the MDM2 inhibito...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Courtney D. DiNardo, Rebecca Olin, Eunice S. Wang, Barry Skikne, Joseph Rosenthal, Prasanna Kumar, Hiroyuki Sumi, Yoshiyuki Hizukuri, Ying Hong, Parul Patel, Takahiko Seki, Tao Duan, Arnaud Lesegretain, Michael Andreeff
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Wiley 2024-07-01
سلاسل:	Cancer Medicine
الموضوعات:	acute myeloid leukemia milademetan mouse double minute‐2 homolog myelodysplastic syndromes
الوصول للمادة أونلاين:	https://doi.org/10.1002/cam4.70028
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!